lazucirnon (AKST4290) / Grifols 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
3 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
lazucirnon (AKST4290) / Grifols
2019-002821-31: A clinical study to assess the effect of AKST4290 in patients with age-related macular degeneration

Not yet recruiting
2
15
Europe
AKST4290, AKST4290, Film-coated tablet
Alkahest, Inc, Alkahest, Inc
Age-related macular degeneration, Age-related macular degeneration, Diseases [C] - Eye Diseases [C11]
 
 
2019-001657-42: A study to learn how well the drug AKST4290 works and how safe AKST4290 is in people who have Parkinson's disease that are taking dopamine based medication.

Not yet recruiting
2
120
Europe
AKST4290, AKST4290, Film-coated tablet
Alkahest, Inc., Alkahest, Inc.
Parkinson's Disease, Parkinson's disease is a disease that affects the brain and nerves, which causes the patients muscles to shake and causes movement to be rigid and imprecise. The condition gets worse over time., Diseases [C] - Nervous System Diseases [C10]
 
 
2019-001059-37: Double-Blind, Randomized, Placebo-Controlled Trial of AKST4290 for Adjunctive Treatment of Mild to Moderate Bullous Pemphigoid

Not yet recruiting
2
30
Europe, RoW
AKST4290, AKST4290, Film-coated tablet
Alkahest, Inc., Alkahest, Inc.
Mild to Moderate Bullous Pemphigoid, Mild to Moderate Bullous Pemphigoid, Diseases [C] - Skin and Connective Tissue Diseases [C17]
 
 

Download Options